News

In the podcast, Kent Thoelke, Executive Vice Presdient, Scientific & Medical Affairs for PRA, discuss parallel drug development strategies in China, the nuances of the regulatory market there, as well as best practices.

When the EMA and the FDA both released their views on risk-based approaches to clinical trials in August 2011, a light appeared for sponsors looking for relief in the way they manage resources in clinical trials.

Sponsors, CROs, regulators, sites and opinion leaders have discussed the pros and cons of a risk-based approach to field monitoring for years. The pharmaceutical industry always sought guidance from the FDA, and different approaches for reviewing data collected by sites.

Medidata Solutions

Improving diversity, education, and advancement in studies: a look at the IDEAS initiative.

The Avoca Group's "2012 Industry Survey," sponsors and service providers were asked to share their experiences with strategic partnerships.